FOXO4-DRI
The star senolytic peptide of 2017 in mice; in humans, the hype is far ahead of the data.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
FOXO4-DRI is a D-retro-inverso peptide designed to interfere with the FOXO4–p53 interaction in senescent cells, pushing them into apoptosis. The key paper is Baar et al., Cell 2017 (not Nature): in mice, it improved fitness, fur, and kidney function during aging, and mitigated doxorubicin toxicity. There is no established human clinical program published for this peptide as a longevity senolytic. Compare with better-characterized senolytics in trials (e.g., dasatinib+quercetin) — they are different compounds.
Studied for
How it works
In senescence, FOXO4 helps maintain viability via p53. The peptide competes for this interaction → nuclear exclusion of p53 → selective apoptosis of senescent cells (in the described model).
What the research says
Foundational: PubMed 28340339 / PMC5556182. Humans: no robust trials of commercial FOXO4-DRI. Senolytic field: reviews from Nature Rev Drug Disc and senolytics literature — the landscape is broader than this peptide.
Evidence level
D — foundational preclinical; no human RCTs of the peptide
What's most reported
- In mice: less senescence, improved function in aging models
- On forums: anecdotal “anti-aging”
Common side effects
Unknown in humans. Eliminating senescent cells is theoretically not harmless (wound healing, regeneration). Research products: variable quality.
Combines / does not combine
Senolytic stacks from forums are speculative. There is no demonstrated clinical synergy with Rapamycin, NAD+, etc.
Frequently asked questions
It has not been demonstrated. The strong paper is in mice (2017).
Not comparable: different evidence and different clinical maturity.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidelines. Research products are not approved drugs unless otherwise indicated.